Table 2.

Clinical and surgical characteristics of 13 patients harboring EGFRvIII-positive glioblastomas

Patient	Age	Sex	OP	MGMT	P1 (%)	P2 (%)	RT	TMZ	Rec	Treatment at recurrence	OS (m)	D/A
1	59	M	GTR	−	36	0	+	+	PD	Surgery, TMZ	62	A
2	81	M	PR	+	19	−	+	+	PD	TMZ	14	D
3	75	F	STR	−	34	−	+	+	PD	TMZ, Bev	34	D
4	59	M	GTR	+	48	0	+	+	PD	TMZ, RT	13	D
5	67	M	STR	−	56	0	+	+	PD	TMZ, Bev	36	D
6	67	F	PR	−	31	−	+	+	PD	TMZ	21	D
7	81	M	STR	+	42	−	+	−	PD	TMZ, RT, Bev	13	D
8	72	M	STR	−	21	−	+	+	PD	−	8	D
9	76	F	STR	−	100	0	+	+	PD	−	16	A
10	48	M	STR	+	39	−	+	+	PD	Bev	12	A
11	69	M	STR	+	94	0	+	+	PD	Surgery	9	D
12	62	M	STR	+	49	0	+	+	SD	−	5	A
13	69	M	GTR	+	26	−	+	+	PD	Bev, TMZ	15	A

A: alive, Bev: bevacizumab, D: dead, GTR: gross total resection, OS: overall survival, P1: EGFRvIII-positive ratio in the cellular component, P2: EGFRvIII-positive ratio in the tumor periphery, PD: progressive disease, PR: partial resection, SD: stable disease, STR: subtotal resection, Rec: recurrence, RT: radiation therapy, TMZ: temozolomide.